Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Dreavent Capital is a venture fund based in Boston, founded over 14 years ago. The firm focuses on investing in the biotech sector, particularly in emerging U.S. biopharma companies. Dreavent aims to convert scientific research into innovative patient treatments, emphasizing the importance of advancing healthcare through biotechnology.
Over the years, Dreavent has established itself as a key player in the biotech investment landscape, actively supporting companies that are pioneering new therapies. The firm has made significant investments in various biotech firms, showcasing its commitment to fostering innovation in the healthcare sector.
Dreavent Capital invests in biotech firms specializing in several critical areas, including oncology, neurology, cardiovascular & metabolic, and immunology. The firm targets investments at various stages, including seed, Series A, Series B, and growth equity, allowing it to engage with companies at different points in their development.
Particularly, Dreavent emphasizes immunology due to its potential for developing new therapies that can significantly impact patient care. The firm seeks sectors that are ripe for innovation and investment returns, aligning its investment strategy with areas that promise substantial advancements in medical treatments.
Dreavent Capital has invested in several notable companies within the biotech sector, including:
This portfolio reflects Dreavent's commitment to supporting innovative solutions in the biotech field, particularly those that address significant healthcare challenges.
To pitch Dreavent Capital, founders should visit their website at dreaventcapital.com. A well-structured pitch deck should include details about the team, product, market opportunity, and financial projections. While specific response times are not mentioned, founders are encouraged to provide a compelling narrative that aligns with Dreavent's investment focus.
What are Dreavent Capital's investment criteria?
Dreavent Capital focuses on biotech firms specializing in oncology, neurology, cardiovascular & metabolic, and immunology. The firm invests at various stages, including seed, Series A, Series B, and growth equity.
How can I pitch to Dreavent Capital?
Founders can pitch to Dreavent Capital by visiting their website at dreaventcapital.com. Specific details on the pitch process are available there.
What makes Dreavent Capital different from other investors?
Dreavent Capital emphasizes sectors that are ripe for innovation, particularly in immunology, which is a key area of focus for the firm. Their commitment to converting scientific research into patient treatments sets them apart.
What is Dreavent Capital's geographic focus?
The firm primarily invests in emerging U.S. biopharma companies, concentrating its efforts in North America.
What is the typical check size for investments?
While specific check sizes are not disclosed, Dreavent Capital invests across various stages, indicating a flexible approach to funding amounts based on the company's needs and growth potential.
How involved is Dreavent Capital post-investment?
Dreavent Capital actively supports its portfolio companies, providing resources and guidance to help them navigate the challenges of the biotech industry.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.